BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 178.7% from a year ago
Total assets stood at $417.65M at the end of Q1 FY2026, up 178.7% from a year earlier and down 6.9% from the prior quarter. Over 3 fiscal years it compounded at +1358.3% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +178.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 448.38M USD
- Year-over-year change
- +130.6%
- 4-year CAGR
- +646.6%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 448.38M | +130.6% |
| FY2024 | 2024-12-31 | 194.42M | +58304.2% |
| FY2023 | 2023-12-31 | 332.89K | +130.3% |
| FY2022 | 2022-12-31 | 144.58K | +0.2% |
| FY2021 | 2021-12-31 | 144.28K | — |
Total Assets vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +178.7% is the 2nd highest of 10, against a peer median of +2.5%.
- Over three fiscal years its annual growth of +1358.3% compares with a peer median of +13.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Aug 2026 | $1.2B USD | +128.8% | +18.2% | |
| Sep 2026 | $1.03B USD | +391.8% | -3.0% | |
| Jun 2026 | $724.96M USD | -17.6% | +1.1% | |
SEPNSepterna, Inc. | Sep 2026 | $619.4M USD | +2.1% | +154.6% |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $417.65M USD | +178.7% | +1358.3% |
| Mar 2026 | $329.68M USD | -21.9% | -15.8% | |
| Mar 2026 | $305.12M USD | +3.7% | +16.3% | |
| Mar 2026 | $253.69M USD | +2.5% | +13.9% | |
| Mar 2026 | CHF 243.26M CHF | +19.1% | +85.4% | |
| Sep 2026 | $209.41M USD | -4.0% | -19.2% | |
| Peer median (excluding BBOT) | — | +2.5% | +13.9% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.